EGFR and non-small cell lung carcinoma: EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib and afatinib, have produced dramatic responses in patients with EGFR-positive NSCLC, as evidenced by significant improvements in the response rate (RR) and survival compared with patients treated with platinum doublet-based chemotherapy as first-line therapy.